Swedbank AB Grows Stock Position in AbbVie Inc. $ABBV

Swedbank AB increased its holdings in AbbVie Inc. (NYSE:ABBV) by 22.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,396,920 shares of the company’s stock after buying an additional 444,441 shares during the quarter. Swedbank AB’s holdings in AbbVie were worth $521,306,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Integrated Advisors Network LLC raised its position in AbbVie by 30.3% in the first quarter. Integrated Advisors Network LLC now owns 47,509 shares of the company’s stock worth $10,333,000 after acquiring an additional 11,057 shares during the period. Kiley Juergens Wealth Management LLC bought a new stake in shares of AbbVie during the 1st quarter valued at $1,587,000. Walser Wealth Management Company A Ltd Liability Co purchased a new stake in shares of AbbVie in the 1st quarter worth $336,000. Collaborative Fund Advisors LLC purchased a new stake in shares of AbbVie in the 1st quarter worth $551,000. Finally, Arbor Investment Advisors LLC raised its holdings in AbbVie by 32.8% in the 1st quarter. Arbor Investment Advisors LLC now owns 1,921 shares of the company’s stock worth $418,000 after purchasing an additional 475 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a European Commission approval for TEPKINLY (epcoritamab) plus lenalidomide and rituximab to treat relapsed or refractory follicular lymphoma. The approval expands the drug’s reach in Europe and supports AbbVie’s oncology growth story. Article: AbbVie Announces TEPKINLY approval by the European Commission
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 and kept an overweight rating, signaling continued analyst confidence in the stock’s upside. Article: AbbVie price target raised by Cantor Fitzgerald
• Neutral Sentiment: AbbVie is also getting some investor focus ahead of its upcoming quarterly report, with analysts watching whether Skyrizi and Rinvoq can offset continued pressure from Humira declines. Article: Will Immunology Franchise Aid AbbVie’s Upcoming Q2 Results?
• Negative Sentiment: AbbVie cut its second-quarter 2026 EPS guidance to $3.57-$3.61, below the consensus estimate of $3.77, which could pressure shares. FY 2026 EPS guidance was also lowered to $13.91-$14.11 versus the Street’s $14.25 forecast.

AbbVie Price Performance

Shares of AbbVie stock traded up $2.67 during trading on Tuesday, reaching $257.43. 1,367,833 shares of the stock traded hands, compared to its average volume of 7,174,337. AbbVie Inc. has a 52-week low of $184.63 and a 52-week high of $261.64. The business has a fifty day simple moving average of $221.27 and a two-hundred day simple moving average of $220.47. The company has a market capitalization of $454.83 billion, a price-to-earnings ratio of 126.66, a P/E/G ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.46 earnings per share. On average, research analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Analysts Set New Price Targets

ABBV has been the subject of a number of analyst reports. Guggenheim restated a “buy” rating and issued a $249.00 price target on shares of AbbVie in a research report on Friday, May 1st. Piper Sandler reiterated an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research note on Tuesday, June 23rd. Evercore set a $235.00 target price on shares of AbbVie in a report on Friday, May 15th. HSBC reaffirmed a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday. Finally, Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $256.67.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.